Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III trial of tesetaxel as second-line therapy in Gastric cancer

Next Previous
Trial Profile

Phase III trial of tesetaxel as second-line therapy in Gastric cancer

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 05 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tesetaxel (Primary)
  • Indications Gastric cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Genta (CEASED)

Most Recent Events

  • 29 Jun 2011 A request for Special Protocol Assessment (SPA) will be submitted to the US FDA in Q3 of 2011, according to Genta media release.
  • 04 Jun 2011 Phase II results presented at ASCO suggest a starting dose of 27 mg/m2 with escalation to 35 mg/m2. The trial will proceed with a q3w schedule.
  • 16 Dec 2010 The trial could commence in 2011, pending completion of global regulatory review, according to a Genta media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top